The damage caused by Alzheimer's disease begins long before any symptoms show up. Over the course of years or decades in this preclinical stage, the characteristic buildup of disease-causing amyloid ...

Discover whether it's possible to have mixed dementia, specifically a combination of Alzheimer's and Lewy body dementia. This ...

SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may ...

Alzheimer’s is caused by specific brain changes called amyloid plaques and neurofibrillary tangles. However, FTD is actually a group of different diseases with various causes. This makes it ...

Researchers have revealed the role of enzyme TYK2 in the aggregation of tau proteins, which contributes to Alzheimer’s ...

A drug used to treat glaucoma holds promise in the fight against various forms of dementia, according to University of ...

Dementia, a term encompassing a decline in cognitive function, is a complex and often misunderstood condition. More than 55 ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...

Aneuro provides high-quality Tau products — proteins, fibrils, cell lines, and antibodies. These products assist researchers ...

Veravas, Inc., a leading innovator in clinical diagnostics, today announced a collaboration with Phanes Biotech to co-develop a blood-based Alzheimer’s disease (AD) tau pathology test. Phanes Biotech ...

The following is a summary of “Cerebral Amyloid Angiopathy, Dementia, and Alzheimer Neuropathologic Changes: Findings From ...

The MAPT transgene is driven by the rat Prnp promoter. Overexpress the 0N4R isoform of human tau with the P301S mutation Homozygotes develop neurofibrillary tangles, exhibit neurodegeneration, and die ...